Target intelligence / Profile preview

Butyrophilin subfamily 2 member A1–Butyrophilin subfamily 3 member A1 complex (BTN2A1–BTN3A1 complex) (BTN2A1–BTN3A1 complex)

Target
BTN2A1–BTN3A1 complex
Molecular classification
Butyrophilin family, Immunoglobulin superfamily, Receptor, Immune checkpoint
01

Overview

The Butyrophilin subfamily 2 member A1–Butyrophilin subfamily 3 member A1 (BTN2A1–BTN3A1) complex is a heteromeric protein assembly that serves as a critical molecular sensor for metabolic stress and infection in humans [2, 12]. It is the primary mediator for the activation of Vγ9Vδ2 T cells, a major subset of gamma-delta T cells that provide rapid, MHC-unrestricted immune responses against malignant and infected cells [3, 16]. The complex functions through an "inside-out" signaling mechanism: intracellular phosphoantigens (pAgs), such as isopentenyl pyrophosphate (IPP) or microbial HMBPP, bind to the B30.2 domain of BTN3A1, acting as a molecular glue that promotes its association with BTN2A1 [2, 14]. This intracellular interaction induces a conformational change in the extracellular domains, allowing BTN2A1 to bind directly to the Vγ9 chain of the T cell receptor (TCR) [4, 18]. In oncology, this complex is a high-priority therapeutic target; agonistic monoclonal antibodies like ICT01 are designed to stabilize the complex and bypass the requirement for high pAg levels, thereby potently activating gamma-delta T cells to eliminate a wide range of solid and hematologic tumors [9, 11].

Other names
Butyrophilin 2A1/3A1 complexBTN2A1-BTN3A1 heterodimerHMBPP receptor complexCD277 complex
02

Mechanism of action

Agonistic activation of Vγ9Vδ2 T cells by stabilizing the heteromeric association between BTN2A1 and BTN3A1, which facilitates the engagement of the gamma-delta T cell receptor (TCR) and subsequent cytotoxic activity against target cells [2, 9].

03

Biological functions

Immune responseSignal transductionPhosphoantigen sensingGamma-delta T cell activation
04

Disease associations

CancerInfectionInflammation
05

Safety considerations

Cytokine release syndrome (CRS)Potential for autoimmune reactionsOff-target immune activation
06

Interacting drugs

ICT01

4 more in the full profile.

07

Biomarkers

Soluble BTN2A1 (sBTN2A1)BTN3A1 expression levelsVγ9Vδ2 T cell frequency

Beyond the preview

Go deeper on Butyrophilin subfamily 2 member A1–Butyrophilin subfamily 3 member A1 complex (BTN2A1–BTN3A1 complex) (BTN2A1–BTN3A1 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butyrophilin subfamily 2 member A1–Butyrophilin subfamily 3 member A1 complex (BTN2A1–BTN3A1 complex) (BTN2A1–BTN3A1 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call